| Symbol | AORT |
|---|---|
| Name | ARTIVION, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 1655 ROBERTS BOULEVARD NORTH WEST, KENNESAW, Georgia, 30144, United States |
| Telephone | +1 770 419-3355 |
| Fax | — |
| — | |
| Website | https://www.artivion.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000784199 |
| Description | Artivion is a leader in the manufacturing processing and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. Our purpose is to develop simple elegant solutions that address cardiac and vascular surgeons most difficult challenges in treating patients with diseases of the aorta and deliver breakthrough technologies of unsurpassed quality that have far-reaching impact. Our decades of expertise in treating aortic diseasescoupled with our recent acquisitions and partnershipshave empowered us to offer cardiac and vascular surgeons a suite of aortic-centric solutions such as cryopreserved cardiac and vascular allografts surgical sealants prosthetic heart valves and aortic stents and stent-grafts. Artivion has over 1250 employees worldwide with sales representation in over 100 countries. The Company has manufacturing facilities located in Atlanta Georgia Austin Texas and Hechingen Germany. Additional info from NASDAQ: |
GREEN ANDREW M 🔴 sold 11.5K shares of ARTIVION, INC. (AORT) at $24.97 Transaction Date: Sep 10, 2026 | Filing ID: 061602
Read more📋 GREEN ANDREW M (Officer) plans to sell 11K shares of ARTIVION, INC. (at $24.97 each, total $287K) Filed: Sep 10, 2026 | ID: 006850
Read moreGREEN ANDREW M 🔴 sold 8.0K shares of ARTIVION, INC. (AORT) at $27.27 Transaction Date: Sep 02, 2026 | Filing ID: 060667
Read more📋 GREEN ANDREW M (Officer) plans to sell 7K shares of ARTIVION, INC. (at $27.27 each, total $177K) Filed: Sep 02, 2026 | ID: 006673
Read more📋 Stanton Marshall S. (Officer) plans to sell 7K shares of ARTIVION, INC. (at $26.85 each, total $199K) Filed: Aug 27, 2026 | ID: 006490
Read moreMackin James P 🔴 sold 70.0K shares of ARTIVION, INC. (AORT) at $28.95 ($2.0M) Transaction Date: Aug 19, 2026 | Filing ID: 058212
Read more📋 Mackin James P (Officer) plans to sell 70K shares of ARTIVION INC (at $29.33 each, total $2.1M) Filed: Aug 19, 2026 | ID: 006228
Read moreGREEN ANDREW M 🔴 sold 616 shares of ARTIVION, INC. (AORT) at $28.55 Transaction Date: Aug 14, 2026 | Filing ID: 057330
Read moreBerry Lance A 🔴 sold 715 shares of ARTIVION, INC. (AORT) at $28.55 Transaction Date: Aug 14, 2026 | Filing ID: 057327
Read more📋 Berry Lance A (Officer) plans to sell 715 shares of ARTIVION, INC. (at $28.55 each, total $20K) Filed: Aug 14, 2026 | ID: 006039
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07413926 | Mitral Valve Repair With the Chord-X System: A Long Term Evaluation | — | Mitral Regurgitation (MR) | Not_Yet_Recruiting | 2026-06-01 | 2034-06-01 | ClinicalTrials.gov |
| NCT07089576 | Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA | Na | Aortic Arch Aneurysm | Recruiting | 2025-11-04 | 2032-07-01 | ClinicalTrials.gov |
| NCT05174767 | PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection | Na | Acute Aortic Dissection | Active_Not_Recruiting | 2022-05-27 | 2029-12-06 | ClinicalTrials.gov |
| NCT05314868 | Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in… | — | Congenital Heart Disease | Terminated | 2022-03-31 | 2022-11-30 | ClinicalTrials.gov |
| NCT04142658 | PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can … | Phase3 | Aortic Valve Disease | Terminated | 2020-05-01 | 2022-12-12 | ClinicalTrials.gov |
| NCT03669042 | Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vas… | Na | Vascular Diseases | Completed | 2018-11-20 | 2020-07-10 | ClinicalTrials.gov |
| NCT03397251 | DARTS I: Feasibility, Safety, and Performance Trial | Na | Acute DeBakey I Aortic Dissection | Completed | 2018-03-07 | 2024-01-23 | ClinicalTrials.gov |
| NCT03035643 | DARTS I Feasibility Study | Na | Aortic Dissection | Completed | 2017-03-05 | 2024-03-19 | ClinicalTrials.gov |
| NCT02359994 | Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation … | Na | Blood Loss, Surgical | Completed | 2015-04-01 | 2019-02-20 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arista AH | Other | Approved | Blood Loss, Surgical | COMPLETED | NCT02359994 |
| PerClot Polysaccharide Hemostatic System | Other | Approved | Blood Loss, Surgical | COMPLETED | NCT02359994 |
| PhotoFix | Other | Preclinical | Congenital Heart Disease | TERMINATED | NCT05314868 |
| On-X Aortic Mechanical Valve | Other | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Warfarin | Other | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Apixaban 2.5 MG | Other | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Apixaban 5 MG | Other | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| AMDS | Other | Approved | Acute DeBakey I Aortic Dissection | COMPLETED | NCT03397251 |
| AMDS | Other | Approved | Aortic Dissection | COMPLETED | NCT03035643 |
| PhotoFix | Other | Approved | Vascular Diseases | COMPLETED | NCT03669042 |
| AMDS | Other | Approved | Acute Aortic Dissection | ACTIVE_NOT_RECRUITING | NCT05174767 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Arcevo™ LSA Hybrid Stent Graft System | Other | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| Chord-X system implant | DEVICE | Preclinical | Mitral Regurgitation (MR) | NOT_YET_RECRUITING | NCT07413926 |
| Arcevo™ LSA Hybrid Stent Graft System | DEVICE | Approved | Aortic Arch Aneurysm | RECRUITING | NCT07089576 |
| On-X Aortic Mechanical Valve | DEVICE | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Warfarin | DRUG | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Apixaban 2.5 MG | DRUG | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| Apixaban 5 MG | DRUG | Phase PHASE3 | Aortic Valve Disease | TERMINATED | NCT04142658 |
| PhotoFix | DEVICE | Preclinical | Congenital Heart Disease | TERMINATED | NCT05314868 |
| AMDS | DEVICE | Approved | Acute Aortic Dissection | ACTIVE_NOT_RECRUITING | NCT05174767 |
| Arista AH | DEVICE | Approved | Blood Loss, Surgical | COMPLETED | NCT02359994 |
| PerClot Polysaccharide Hemostatic System | DEVICE | Approved | Blood Loss, Surgical | COMPLETED | NCT02359994 |